Arbutus Biopharma Corporation (NASDAQ:ABUS) saw a downside of -0.48% to close Friday at $2.06 after subtracting -$0.01 on the day. The 5-day average trading volume is 867,500 shares of the company’s common stock. It has gained $2.15 in the past week and touched a new high 3 times within the past 5 days. An average of 609,475 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 645,204.
ABUS’s 1-month performance is -8.44% or -$0.15 on its low of $1.98 reached on 08/16/23. The company’s shares have touched a 52-week low of $1.85 and high of $3.14, with the stock’s rally to the 52-week high happening on 03/30/23. YTD, ABUS has lost -11.59% or -$0.27 and has reached a new high 18 times. However, the current price is down -34.50% from the 52-week high price.
Valuation Metrics
ABUS stock has a beta of 2.11. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 14.76 while the price-to-book (PB) in the most recent quarter is 2.54.
Arbutus Biopharma Corporation’s quick ratio for the period ended June 29 was 6.50, with the current ratio over the same period at 6.50. The trailing 12-month EBITDA margin is -158.37%. The firm’s gross profit as reported stood at $104.47 million against revenue of $39.02 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 16.97% to -$17.09 million, while revenue of -$16.34 million was 4.39% off the previous quarter. Analysts expected ABUS to announce -$0.11 per share in earnings in its latest quarter, but it posted -$0.1, representing a 9.10% surprise. EBITDA for the quarter stood at more than -$18.04 million. ABUS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 42.13 million, with total debt at $2.04 million. Shareholders hold equity totaling $167.56 million.
Let’s look briefly at Arbutus Biopharma Corporation (ABUS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 45.52% to suggest the stock is trending Neutral, with historical volatility in this time period at 26.60%.
The stock’s 5-day moving average is $2.03, reflecting a +0.98% or $0.02 change from its current price. ABUS is currently trading -5.07% above its 20-day SMA, -32.68% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -21.37% and SMA200 by-11.97%.
Stochastic %K and %D was 31.88% and 21.61% and the average true range (ATR) pointed at 0.08. The RSI (14) points at 42.03%, while the 14-day stochastic is at 34.78% with the period’s ATR at 0.08. The stock’s 9-day MACD Oscillator is pointing at 0.02 and -0.01 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Arbutus Biopharma Corporation (NASDAQ: ABUS), Jefferies upgraded it to a Buy rating. They previously had a Hold rating on the stock. Analysts offering their rating for ABUS stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ABUS as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is ABUS’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $6.00, with their median price target at $6.00. Looking at these predictions, the average price target given by analysts is for Arbutus Biopharma Corporation (ABUS) stock is $5.40.
